全国共享全球公开 中国药登系统上线

Core Viewpoint - The establishment of the China Drug Price Registration System (China Drug Registration) aims to create a global drug pricing system, support the high-quality development of innovative drugs, and enhance the integration of China's pharmaceutical industry into international competition [1][4]. Group 1: Announcement and Implementation - The National Healthcare Security Administration (NHSA) and the Beijing Municipal Government jointly launched the China Drug Registration, providing a platform for drug price registration and inquiry services [3]. - The registration will initially focus on innovative drugs and gradually expand to other drugs, allowing pharmaceutical companies to self-declare prices while ensuring the authenticity of the information [3][5]. Group 2: Independence and Pricing Mechanism - China Drug Registration operates independently from provincial medical procurement platforms, ensuring that registered prices do not alter the pricing levels for insured and uninsured patients [5][6]. - The registration system allows for the disclosure of market prices, which can be used for international price comparisons, enhancing the competitiveness of Chinese pharmaceutical companies in the global market [6][7]. Group 3: Global Market Integration - The establishment of China Drug Registration facilitates the "going out" strategy for Chinese innovative drugs and attracts high-quality foreign drugs into the Chinese market [7][8]. - The system supports Chinese companies in gaining global market recognition and establishing international brand influence, which is crucial for their valuation and future research and development [7]. Group 4: Participation of Foreign Companies - The first batch of registered companies includes both domestic and foreign pharmaceutical firms, indicating a collaborative approach to enhance the availability of innovative drugs in China [8]. - The independent pricing mechanism of China Drug Registration is expected to attract multinational pharmaceutical companies to participate in national healthcare negotiations, thereby increasing the availability of innovative drugs in the Chinese market [8].